The American Journal of Managed Care
The American Journal of Managed Care, known throughout American health policy by its initials AJMC, is a peer-reviewed medical journal devoted to a question most clinical journals treat as background: how care is organised, paid for and judged on outcomes. Founded in 1995 and published monthly from Cranbury, New Jersey, by MJH Life Sciences, it provides a forum for research on health care outcomes in a cost-constrained system. Its readers are not only physicians but the medical directors, pharmacy leaders and benefits decision-makers who decide which care gets covered and how it is delivered.
That positioning has made AJMC a distinctive institution. Clinical journals ask whether a treatment works; AJMC also asks what it costs, who gains access to it, how a payment model changes behaviour, and whether an intervention improves outcomes in ordinary practice rather than in a trial. Three decades after its founding — a milestone the journal marked in September 2025 — it remains the leading peer-reviewed publication dedicated specifically to managed care.
Founded in 1995, During a Managed Care Reckoning
AJMC's own history of itself notes that it was founded in 1995, during the last great period of serious re-examination of how American health care is paid for and delivered. The mid-1990s were the height of the first managed care era, when health maintenance organisations, utilisation review and capitation were reshaping the relationship between doctors, insurers and patients, and provoking a fierce public and professional debate about cost control.
A journal created in that moment had a clear gap to fill. The evidence base for managed care — what worked, what harmed access, what saved money without harming outcomes — was thin and scattered across clinical, economic and policy publications. AJMC set out to be the place where that literature gathered, evaluated by peer review and addressed to the people making coverage and delivery decisions. When payment and delivery reform returned to the centre of American health policy in the following decades, the journal's founding subject had become the system's central question again.
Peer Review and What Gets Published
AJMC describes itself as an independent, peer-reviewed publication, and its evaluation process is deliberately demanding. All original articles undergo rigorous peer review by leading clinical investigators, health services researchers and clinical epidemiologists. Manuscripts are additionally assessed for real-world relevance — a criterion that distinguishes the journal from outlets content with methodological soundness alone. Research that cannot inform a decision in practice is a weaker fit for its pages, however elegant its design.
The journal can publish only a fraction of what it receives, approximately 35 percent of submissions. Alongside original research it publishes review articles, commentaries, trends from the field, editorials and letters to the editor. That mix reflects its dual identity: a scholarly journal whose findings are cited in the research literature, and a professional forum in which the implications of those findings are argued out by the people who run health plans, pharmacy benefit programmes, hospitals and delivery systems.
Readership: The Decision-Makers of Managed Care
The journal circulates to approximately 30,000 individuals with decision-making responsibilities affecting access to and utilisation of health care resources. Its audience profile is unusually specific for a medical journal. Readers include medical directors, members of pharmacy and therapeutics committees, pharmacy directors, physicians, and corporate benefits managers, spread across six market segments: HMO, PPO and integrated health organisations; hospitals; long-term care; pharmacy benefit managers; the Department of Veterans Affairs and government; and employers.
That readership explains the journal's editorial choices. An article on a formulary decision, a biosimilar substitution policy or a value-based contract is written for readers who may act on it at the next committee meeting. AJMC is, in effect, the trade's scholarly journal and the scholars' trade journal at once — a bridge between health services research and the operational world of American managed care, published in print with ISSN 1088-0224 and online with ISSN 1936-2692, and indexed in MEDLINE.
Scope: Outcomes, Policy and the Cost-Constrained Clinic
The journal states its territory plainly: it addresses a broad range of issues relevant to clinical decision-making in a cost-constrained environment, and examines the impact of clinical, management and policy interventions and programmes on health care and economic outcomes. In practice that spans health outcomes research, comparative effectiveness, pharmacoeconomics, population health, care management programmes, benefit design, and the evaluation of payment reforms such as accountable care and bundled payment.
Value-based care has become the organising theme of its modern coverage. AJMC's leadership has framed the journal's mission around connecting rigorous clinical and managerial research to policy and decision-makers, and around disseminating findings more effectively than a conventional journal cycle allows. Its editor in chief, A. Mark Fendrick, MD — a prominent voice in value-based insurance design — articulated that ambition at the 30th anniversary: going beyond the typical journal to get key findings into the hands of the people who shape care.
Beyond the Journal: The Managed Markets Network
AJMC began as a print journal but grew into the foundation of a broader managed markets network. By its 25th anniversary in 2020, the brand encompassed the Peer Exchange and Insights video series, in which panels of experts discuss research and policy on camera; online news coverage; post-conference reporting; and live events. The journal's website publishes news and interviews alongside the formal literature, so that a fast-moving policy story and a slow-moving outcomes study sit within the same brand.
Sister publications extend the family. The American Journal of Accountable Care addresses delivery systems taking responsibility for populations and budgets, while Evidence-Based Oncology applies the journal's value lens specifically to cancer care, including the long-running debate over how to define value in oncology — the subject of supplements featuring the architects of value frameworks from academic cancer centres, professional societies and assessment institutes. Supplements of this kind, often developed from expert roundtables, are a established part of the AJMC model, translating specialist consensus into a citable record for the field.
Events: The Institute for Value-Based Medicine and PCOC
The events arm is substantial. The Institute for Value-Based Medicine, known as IVBM, runs regional programmes across the United States that bring together providers, payers, pharmacists and administrators to examine how value-based care is actually being implemented across specialties and service lines. Each programme is tuned to the disease states and therapeutic areas that matter most to its local market while keeping a national perspective on value, outcomes and cost containment, with expert panels, cross-disciplinary discussion and an emphasis on strategies attendees can implement immediately.
Patient-Centered Oncology Care, or PCOC, is AJMC's national oncology conference, convening leaders across the cancer care continuum to address policy, reimbursement, innovation and patient-centred delivery models. Its agenda runs from oncology reform and evolving payment models to precision medicine, access and equity, and its audience of payers, providers, pharmacy leaders and policy experts mirrors the journal's readership in person. Together, IVBM and PCOC embody the journal's stated belief that the conversation should extend beyond the page and into the room.
Anniversaries and Continuity
The journal's milestone years offer a useful record of its self-understanding. At 25 years, in 2020, its publisher emphasised trust and integrity — providing a forum for peer-reviewed literature on health care outcomes research while shining a light on health policy for industry decision-makers. At 30 years, in 2025, the emphasis had shifted to the future of value-based care: the anniversary was marked with a dedicated web presence collecting milestones, highlights and testimonials, and with a restated commitment to equipping health care stakeholders for a rapidly changing industry.
Across those three decades the environment changed repeatedly — the managed care backlash, the rise of pharmacy benefit management, the Affordable Care Act, the spread of value-based payment, the arrival of high-cost specialty and cell and gene therapies — and each wave enlarged rather than shrank the journal's remit. A publication founded to scrutinise how care is managed found, in each era, that management had become more consequential, not less.
Ownership and Publishing Home
AJMC is a brand of MJH Life Sciences, described by the company as the largest privately held, independent, full-service medical media company in North America. The journal's publishing operation is based in Cranbury, New Jersey, at the same campus that houses many of MJH's clinical titles. That home places AJMC alongside sister brands in oncology, urology and other specialties within the MJH portfolio, with the journal formally published by the company's Clinical Care Targeted Communications group.
For a health policy reader, that structure matters mainly in one respect: the journal operates inside a multimedia medical media company rather than a university or professional society, which explains its combination of peer-reviewed scholarship with video series, conferences and news. Its independence as a journal — its own editorial board, peer review and acceptance decisions — is the claim on which its credibility with researchers rests, and it is a claim the journal states explicitly in its own description of its purpose.
Why AJMC Matters
Most of the consequential arguments in American health care are, at bottom, managed care arguments: which therapies a plan covers, how a hospital is paid, whether a preventive service should be free at the point of use, how outcomes should be measured and priced. AJMC is the peer-reviewed venue built specifically for those arguments, written by researchers and read by the executives and clinicians who must act on the answers.
Its aim, in its own formulation, is to stimulate scientific communication in the ever-evolving field of managed care. Thirty years on, with monthly issues continuing into their thirty-second volume in 2026, that communication shows no sign of slowing — because the cost-constrained environment the journal was created to study has become the permanent condition of American medicine.
At a Glance
The American Journal of Managed Care was founded in 1995, is published monthly from Cranbury, New Jersey, by MJH Life Sciences, and is available at ajmc.com. It is an independent, MEDLINE-indexed, peer-reviewed journal publishing original research, reviews, commentaries and editorials on managed care, health outcomes, health policy and population health, read by roughly 30,000 decision-makers across health plans, hospitals, long-term care, pharmacy benefit management, government and employers. Its wider brand includes Evidence-Based Oncology, The American Journal of Accountable Care, Peer Exchange and Insights video, and the Institute for Value-Based Medicine and Patient-Centered Oncology Care events.
